Purpose: We aimed to evaluate and compare relative impacts of various second-line
treatments on overall survival (OS) in metastatic urothelial carcinoma (mUC). Method: A …

381 Background: Atezo (anti–PD-L1) was the first immune checkpoint inhibitor approved for
mUC. Here, we describe pt characteristics, time on tx (TOT) and distribution of tx cycles for …

4515 Background: A majority of mUC patients (pts) treated with chemo ultimately progress,
and subsequent therapy is often accompanied by low ORRs and short OS. Atezo …

Until recently in the United States, no products were approved for second‐line treatment of
advanced urothelial carcinoma. On May 18, 2016, the US Food and Drug Administration …

2017 saw the publication of clinical trial data and the approval of new treatment approaches
for metastatic urothelial carcinoma. Pembrolizumab is now a well-established treatment for …

Introduction: Muscle invasive bladder cancer (MIBC) is difficult to manage for patients who
progress during or after initial chemotherapy regimens. Current regimens offer low response …

LBA4500 Background: Cisplatin-based chemo is a standard 1L treatment (tx) for mUC and
the only tx that prolongs OS; however, age or comorbidities render many pts ineligible, and …

Background Few options exist for patients with locally advanced or metastatic urothelial
carcinoma after progression with platinum-based chemotherapy. We aimed to assess the …

290 Background: Atezo (anti–PD-L1) has demonstrated safety and efficacy in a broad range
of cancers and is approved in the United States for mUC previously treated with platinum …

BACKGROUND: Atezolizumab is an immune checkpoint inhibitor (ICI) and a frontline
treatment of patients with cisplatin-ineligible advanced urothelial carcinoma (UC). There is …